Lyell Immunopharma receives FDA IND clearance for LYL845 TIL therapy for solid tumors

Lyell Immunopharma, Inc.

FDA cleared IND for LYL845, an autologous TIL therapy enhanced with Epi-R reprogramming technology.
Phase 1 trial initially enrolling relapsed/refractory metastatic or locally advanced melanoma; expansion into NSCLC and colorectal cancer.
Initial clinical data expected in 2024; patient screening to begin in coming months.
LYL845 is Lyell's first TIL product candidate and second wholly owned IND clearance within the past year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.